BR0206670A - Compostos halogenados que exibem agonismo para receptor de trombopoietina - Google Patents

Compostos halogenados que exibem agonismo para receptor de trombopoietina

Info

Publication number
BR0206670A
BR0206670A BR0206670-0A BR0206670A BR0206670A BR 0206670 A BR0206670 A BR 0206670A BR 0206670 A BR0206670 A BR 0206670A BR 0206670 A BR0206670 A BR 0206670A
Authority
BR
Brazil
Prior art keywords
receptor agonism
halogenated compounds
compounds exhibiting
thrombopoietin receptor
lower alkyl
Prior art date
Application number
BR0206670-0A
Other languages
English (en)
Inventor
Hiroshi Takemoto
Masami Takayama
Takeshi Shiota
Original Assignee
Shionogi & Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shionogi & Co filed Critical Shionogi & Co
Publication of BR0206670A publication Critical patent/BR0206670A/pt

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/426—1,3-Thiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/02—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings
    • C07D277/20—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D277/32—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D277/38—Nitrogen atoms
    • C07D277/44—Acylated amino or imino radicals
    • C07D277/46—Acylated amino or imino radicals by carboxylic acids, or sulfur or nitrogen analogues thereof

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Abstract

"COMPOSTOS HALOGENADOS QUE EXIBEM AGONISMO PARA RECEPTOR DE TROMBOPOIETINA". A presente invenção refere-se a compostos de fórmula geral (III), pró-drogas dos mesmos, sais farmaceuticamente aceitáveis de ambos ou solvatos dos mesmos e que exibem agonismo para receptor de trombopoietina: em que R^ 9^ é átomo de hidrogênio, alquila inferior opcionalmente substituída ou similares; R^ 10^, R^ 11^e R^ 12^ São cada um independentemente alquila opcionalmente substituída, átomo de halogênio ou similares; R^ 14^ é cada um independentemente alquila inferior, átomo de halogênio ou similares; n é um número inteiro de O a 2; A^ 3^ é um grupo representado pela fórmula: em que R^ 13^ é átomo de hidrogênio ou alquila inferior; T é átomo de oxigênio ou átomo de enxofre.
BR0206670-0A 2001-01-26 2002-01-25 Compostos halogenados que exibem agonismo para receptor de trombopoietina BR0206670A (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
JP2001017785 2001-01-26
JP2001223413 2001-07-24
PCT/JP2002/000547 WO2002059100A1 (fr) 2001-01-26 2002-01-25 Composes halogene ayant un agonisme envers le recepteur de thrombopoietine

Publications (1)

Publication Number Publication Date
BR0206670A true BR0206670A (pt) 2004-02-25

Family

ID=26608322

Family Applications (1)

Application Number Title Priority Date Filing Date
BR0206670-0A BR0206670A (pt) 2001-01-26 2002-01-25 Compostos halogenados que exibem agonismo para receptor de trombopoietina

Country Status (9)

Country Link
US (1) US20040063764A1 (pt)
EP (1) EP1354880A4 (pt)
JP (1) JP4145655B2 (pt)
KR (1) KR20040025891A (pt)
CN (1) CN1516696A (pt)
BR (1) BR0206670A (pt)
CA (1) CA2435143A1 (pt)
MX (1) MXPA03006510A (pt)
WO (1) WO2002059100A1 (pt)

Families Citing this family (39)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect
US20110212054A1 (en) * 2000-05-25 2011-09-01 Glaxosmithkline Llc. Thrombopoietin mimetics
CY2010012I2 (el) 2000-05-25 2020-05-29 Novartis Ag Μιμητικα θρομβοποιητινης
US6875786B2 (en) 2001-03-01 2005-04-05 Smithkline Beecham Corporation Thrombopoietin mimetics
MY142390A (en) * 2002-05-22 2010-11-30 Glaxosmithkline Llc 3' - [(2z)-[1-(3,4-dimethylphenyl)-1,5- dihydro-3- methyl-5-0xo-4h-pyrazol-4- ylidene]hydrazino]-2' -hydroxy -[1,1' -biphenyl]-3-carboxylic acid bis-(monoethanolamine)
EP1552828A4 (en) 2002-08-14 2007-01-24 Nissan Chemical Ind Ltd THROMBOPOIETIN RECEPTOR ACTIVATOR AND METHOD OF PRODUCTION
TWI324593B (en) 2002-10-09 2010-05-11 Nissan Chemical Ind Ltd Pyrazolone compounds and thrombopoietin receptor activator
EP2387998A1 (en) 2003-04-29 2011-11-23 Glaxosmithkline LLC Methods for treating degenerative diseases/injuries
WO2005014561A1 (ja) 2003-08-12 2005-02-17 Shionogi & Co., Ltd. トロンボポエチン受容体アゴニスト作用を有する化合物
TW200526638A (en) 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
TW200524887A (en) * 2003-10-27 2005-08-01 Lundbeck & Co As H N-thiazol-2-yl-benzamide derivatives
MX2007003381A (es) 2004-09-22 2007-04-27 Lundbeck & Co As H Derivados de 2-acilaminotiazol.
CA2581657A1 (en) * 2004-09-23 2006-03-30 Pfizer Products Inc. Thrombopoietin receptor agonists
AU2005312585B2 (en) 2004-12-08 2012-01-12 Nissan Chemical Industries, Ltd. 3-ethylidenehydrazino substituted heterocyclic compounds as thrombopoietin receptor activators
WO2006064957A1 (ja) * 2004-12-14 2006-06-22 Nissan Chemical Industries, Ltd. アミド化合物及びトロンボポエチンレセプター活性化剤
US7674912B2 (en) 2005-04-25 2010-03-09 H. Lundbeck A/S Pro-drugs of N-thiazol-2-yl-benzamide derivatives
AU2006270801B2 (en) * 2005-07-15 2011-12-22 Nissan Chemical Industries, Ltd. Thiophene compounds and thrombopoietin receptor activators
US7960425B2 (en) * 2005-07-20 2011-06-14 Nissan Chemical Industries, Ltd. Pyrazole compounds and thrombopoietin receptor activators
JP2007045946A (ja) * 2005-08-10 2007-02-22 Shipro Kasei Kaisha Ltd チアゾリジン誘導体を用いた有機色素
WO2007044982A2 (en) * 2005-10-13 2007-04-19 Smithkline Beecham Corporation Methods for the preservation of platelet efficacy during storage
EP1947101A4 (en) 2005-11-07 2009-09-16 Nissan Chemical Ind Ltd HYDRAZIDE COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
US7879318B2 (en) * 2006-01-23 2011-02-01 Mcw Research Foundation, Inc. Method of reducing the effects of ischemia by administration of a thrombopoietin receptor ligand
JP2007275058A (ja) * 2006-03-16 2007-10-25 Shionogi & Co Ltd 酵母による不斉還元
EP2025671A4 (en) 2006-06-07 2011-04-06 Nissan Chemical Ind Ltd NITROGENIC HETEROCYCLIC COMPOUND AND THROMBOPOIETIN RECEPTOR ACTIVATOR
US20110129550A1 (en) 2007-02-16 2011-06-02 Connie Erickson-Miller Cancer treatment method
UY30915A1 (es) 2007-02-16 2008-09-02 Smithkline Beecham Corp Método de tratamiento de canceres
ECSP077628A (es) 2007-05-03 2008-12-30 Smithkline Beechman Corp Nueva composición farmacéutica
ES2528196T3 (es) * 2007-07-31 2015-02-05 Shionogi & Co., Ltd. Composición farmacéutica que contiene un compuesto ópticamente activo con actividad agonista del receptor de trombopoyetina, y compuesto intermedio para la misma
AU2008310894B2 (en) 2007-10-09 2012-07-26 Glaxosmithkline Llc Thrombopoietin receptor agonist (TpoRA) kills acute human myeloid leukemia cells
US8476249B2 (en) 2009-05-07 2013-07-02 Glaxosmithkline Llc Method of treating thrombocytopenia
US8680150B2 (en) * 2009-05-28 2014-03-25 Ligand Pharmaceuticals, Inc. Small molecule hematopoietic growth factor mimetic compounds that activate hematopoietic growth factor receptors
EP3127427B1 (en) 2009-05-29 2020-01-08 Novartis Ag Methods of administration of thrombopoietin agonist compounds
AR081331A1 (es) 2010-04-23 2012-08-08 Cytokinetics Inc Amino- pirimidinas composiciones de las mismas y metodos para el uso de los mismos
AR081626A1 (es) 2010-04-23 2012-10-10 Cytokinetics Inc Compuestos amino-piridazinicos, composiciones farmaceuticas que los contienen y uso de los mismos para tratar trastornos musculares cardiacos y esqueleticos
US9133123B2 (en) 2010-04-23 2015-09-15 Cytokinetics, Inc. Certain amino-pyridines and amino-triazines, compositions thereof, and methods for their use
US8759380B2 (en) 2011-04-22 2014-06-24 Cytokinetics, Inc. Certain heterocycles, compositions thereof, and methods for their use
CN105992761A (zh) * 2013-12-20 2016-10-05 盐野义制药株式会社 具有血小板生成素受体激动作用的光学活性的化合物及其中间体的制备方法
JP6658535B2 (ja) 2014-10-31 2020-03-04 日産化学株式会社 リガンド結合繊維及び当該繊維を用いた細胞培養基材
CN112552258B (zh) * 2020-12-22 2023-02-28 许昌学院 噻唑酰胺基异木兰花碱类衍生物及其制备方法和应用

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1989008652A1 (en) * 1988-03-08 1989-09-21 Pfizer Inc. Thiazolidinedione derivatives as hypoglycemic agents
JP3024781B2 (ja) * 1990-08-20 2000-03-21 日清製粉株式会社 ロダニン誘導体
AU707537B2 (en) * 1995-07-31 1999-07-15 Anthera Pharmaceuticals, Inc. Pyrrolidine derivatives having phospholipase a2 inhibitory activity
AU2231397A (en) * 1996-03-08 1997-09-22 Torii Pharmaceutical Co., Ltd. Thiazolidine-2,4-dione derivatives
TW577875B (en) * 1997-01-31 2004-03-01 Shionogi & Co Pyrrolidine derivatives with inhibitory activity for phospholipase A2
JPH10287634A (ja) * 1997-04-11 1998-10-27 Otsuka Pharmaceut Co Ltd ベンゼン誘導体
JPH11152276A (ja) * 1997-11-20 1999-06-08 Hokuriku Seiyaku Co Ltd ベンゾジアゼピン誘導体
GC0000177A (en) * 1998-12-17 2006-03-29 Smithkline Beecham Thrombopoietin mimetics
CN1376150A (zh) * 1999-07-26 2002-10-23 盐野义制药株式会社 具有血栓形成素受体拮抗作用的药物组合物
TWI284639B (en) * 2000-01-24 2007-08-01 Shionogi & Co A compound having thrombopoietin receptor agonistic effect

Also Published As

Publication number Publication date
KR20040025891A (ko) 2004-03-26
WO2002059100A1 (fr) 2002-08-01
EP1354880A1 (en) 2003-10-22
JP4145655B2 (ja) 2008-09-03
EP1354880A4 (en) 2004-08-25
JPWO2002059100A1 (ja) 2004-05-27
CA2435143A1 (en) 2002-08-01
US20040063764A1 (en) 2004-04-01
CN1516696A (zh) 2004-07-28
MXPA03006510A (es) 2003-10-15

Similar Documents

Publication Publication Date Title
BR0206670A (pt) Compostos halogenados que exibem agonismo para receptor de trombopoietina
BR0013251A (pt) Derivado de isoxazolina e herbicida que contém o mesmo como ingrediente ativo
BR0206943A (pt) Inibidores de fosfodiesterase 4
BR0311697A (pt) Novos derivados condensados de imidazol
BR0109851A (pt) Composto, método para produzir o mesmo ou um sal deste, pró medicamento, composição farmacêutica, método para inibir a tirosina cinase, método para prevenir ou tratar câncer, e, uso de um composto ou de um sal ou pró medicamento deste
ATE503746T1 (de) Neue imidazolidinderivate
CY1113657T1 (el) Νεα παραγωγα βενζοφαινονης ή αλατα αυτων
BR0207025A (pt) Derivado de isoxazolina e herbicida contendo o mesmo como o ingrediente ativo
ATE297910T1 (de) Retinoid x rezeptormodulatoren
BR0207863A (pt) Inibidores piridìnicos de metaloproteinases da matriz
BRPI0610312B8 (pt) dispositivo de assistência à caminhada
BR0014541A (pt) Compostos quìmicos
BR9900788A (pt) Compostos ésteres.
BRPI0518068A (pt) composto ou um éster ou sal farmaceuticamente aceitável do mesmo, composição farmacêutica, inibidor seletivo de aurora a, agente anti-tumor, e, preparação combinada
HRP20050775A2 (en) Quinolinone/benzoxazinone derivatives and uses thereof
HUP0002461A2 (hu) Triciklusos benzotiepin- vagy benzoxepinszármazékok és ezeket tartalmazó gyógyszerkészítmények
BR0111019A (pt) 1-aminoalquil-lactamas substituìdas e seu uso como antagonistas de receptores muscarìnicos
ATE374190T1 (de) Tetrahydrochinazolinderivate als cfr-antagonisten
CO5550439A2 (es) Compuestos derivados de arilsulfonil-piperazina que tienen afinidad al receptor 5-ht6 y composiciones farmaceuticas que los contienen
BR0213465A (pt) Compostos de 4-imidazolin-2-ona
BR0208812A (pt) Derivados fenil heterociclil éter como inibidores de recaptação de serotonina
ATE243209T1 (de) Tetrahydro gamma-carboline
BRPI0407441A (pt) 4-[(2,4-dicloro-5-metóxifenil)amino]-6-alcóxi-3-quinoli nacarbonitrilos para o tratamento de lesão isquêmica
DE60130766D1 (de) Serotoninwiederaufnahme-inhibitoren
BRPI0408467A (pt) cromenonaindóis

Legal Events

Date Code Title Description
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE A 5A,6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: REFERENTE AO DESPACHO 8.6 DA RPI 2025 DE 27/10/2009.